ArticleBioresources and bioprocessing2023
Development of a Pichia pastoris cell factory for efficient production of germacrene A: a precursor of β-elemene.
Article in Bioresources and bioprocessing, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- The Mevalonate Pathway: Innovations, Applications, and Challenges in Biotechnology with Emphasis on Fungal Biology.Journal of fungi (Basel, Switzerland) · 2026Review
- Enhancing delta-tocotrienol production inSynthetic and systems biotechnology · 2026Article
- Construction and analysis of a cell factory for terpenoid biosynthesis inSynthetic and systems biotechnology · 2026Article
- EngineeringSynthetic and systems biotechnology · 2025Article
- Biosynthesis of Edible Terpenoids: Hosts and Applications.Foods (Basel, Switzerland) · 2025Review
- Development of a Komagataella phaffii cell factory for sustainable production of ( +)-valencene.Microbial cell factories · 2025Article
- Development of a greenSynthetic and systems biotechnology · 2025Article
- Transcriptome-guided engineering of a native niacin transporter inFrontiers in microbiology · 2025Article
- Transportation engineering for enhanced production of plant natural products in microbial cell factories.Synthetic and systems biotechnology · 2024Review
- Recent advances in lycopene and germacrene a biosynthesis and their role as antineoplastic drugs.World journal of microbiology & biotechnology · 2024Review
- Two-Phase Fermentation Systems for Microbial Production of Plant-Derived Terpenes.Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
β-Elemene, an active ingredient found in medicinal plants like turmeric and zedoary, is a sesquiterpene compound with antitumor activity against various cancers. However, its current mode of production through plant extraction suffers from low efficiency and limited natural resources. Recently, there has been an increased interest in establishing microbial cell factories to produce germacrene A, which can be converted to β-elemene by a one-step reaction in vitro. In this study, we constructed an engineered Pichia pastoris cell factory for producing germacrene A. We rerouted the fluxes towards germacrene A biosynthesis through the optimization of the linker sequences between germacrene A synthase (GAS) and farnesyl pyrophosphate synthase (ERG20), overexpression of important pathway genes (i.e., IDI1, tHMG1, and ACS), and multi-copy integration of related expression cassettes. In combination with medium optimization and bioprocess engineering, the final titer of germacrene A in a 1 L fermenter reached 1.9 g/L through fed-batch fermentation. This represents the first report on the production of germacrene A in P. pastoris and demonstrates its advantage in producing terpenoids and other value-added natural products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.